Apis Capital Advisors LLC Grows Stock Position in Cellebrite DI Ltd. $CLBT

Apis Capital Advisors LLC lifted its stake in Cellebrite DI Ltd. (NASDAQ:CLBT) by 34.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 820,000 shares of the company’s stock after buying an additional 210,000 shares during the period. Cellebrite DI makes up approximately 2.6% of Apis Capital Advisors LLC’s holdings, making the stock its 16th largest holding. Apis Capital Advisors LLC owned about 0.34% of Cellebrite DI worth $14,785,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of CLBT. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Cellebrite DI by 16.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 173,013 shares of the company’s stock worth $3,362,000 after buying an additional 24,881 shares during the period. Geode Capital Management LLC increased its holdings in Cellebrite DI by 16.2% during the 2nd quarter. Geode Capital Management LLC now owns 314,440 shares of the company’s stock valued at $5,029,000 after purchasing an additional 43,898 shares during the period. Invesco Ltd. increased its holdings in Cellebrite DI by 6.4% during the 2nd quarter. Invesco Ltd. now owns 3,505,552 shares of the company’s stock valued at $56,089,000 after purchasing an additional 209,473 shares during the period. First Trust Advisors LP purchased a new position in Cellebrite DI during the 2nd quarter valued at about $341,000. Finally, Marshall Wace LLP purchased a new position in Cellebrite DI during the 2nd quarter valued at about $4,472,000. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Cellebrite DI Stock Performance

Cellebrite DI stock opened at $12.47 on Thursday. The stock’s 50 day simple moving average is $13.15 and its two-hundred day simple moving average is $14.95. The stock has a market cap of $3.11 billion, a price-to-earnings ratio of 44.54, a PEG ratio of 1.59 and a beta of 1.17. Cellebrite DI Ltd. has a fifty-two week low of $11.02 and a fifty-two week high of $19.98.

Insiders Place Their Bets

In other Cellebrite DI news, CRO Marcus Jewell sold 12,658 shares of Cellebrite DI stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $12.77, for a total transaction of $161,642.66. Following the sale, the executive directly owned 440,101 shares of the company’s stock, valued at approximately $5,620,089.77. The trade was a 2.80% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last quarter, insiders sold 13,269 shares of company stock worth $169,592. Insiders own 5.70% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on CLBT shares. Weiss Ratings upgraded Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 18th. Needham & Company LLC reduced their price target on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Wall Street Zen upgraded Cellebrite DI from a “sell” rating to a “hold” rating in a report on Sunday, March 15th. Finally, DA Davidson assumed coverage on Cellebrite DI in a report on Wednesday, May 27th. They set a “buy” rating and a $20.00 price target on the stock. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, Cellebrite DI has an average rating of “Moderate Buy” and a consensus price target of $21.40.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.